Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V (Open-House-Modell)
Description
The subject of this publication is the conclusion of agreements under § 130a para. 8 SGB V for finished medicinal products with various active substances or active substance combinations within the framework of a so-called "Open-House Model". Admission or contract conclusion can take place at any time and on the same conditions. Individual contract negotiations will not be conducted. The earliest contract start date is 01.10.2026. Based on this, the contract duration is a maximum of 24 months. The contract ends on 30.09.2028, regardless of the contract start date. If, during the contract period, AOK Hessen carries out a tender for exclusive contracts in the form of an Open Procedure for the active substances, the contracts concluded within the framework of this publication will be terminated in accordance with the contractual provisions.
CPV codes
Documents & submission
Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.
Related tenders
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Treprostinil, ATC B01AC21
AOK Bayern - Die GesundheitskasseGermanyPharmaceutical productsDeadline in 721 daysPublished on Aug 12, 2026
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Miglustat, ATC A16AX06
AOK Bayern - Die GesundheitskasseGermanyPharmaceutical productsDeadline in 721 daysPublished on Aug 12, 2026
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Erythropoietin, ATC B03AX01 (Kopie)
AOK Bayern - Die GesundheitskasseGermanyPharmaceutical productsDeadline in 721 daysPublished on Aug 12, 2026
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tocilizumab, ATC L04AC07
AOK Bayern - Die GesundheitskasseGermanyPharmaceutical productsDeadline in 721 daysPublished on Aug 12, 2026